Analysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Price Target at $6.55

Key Points

• GoodRx Holdings, Inc. has received a consensus rating of "Moderate Buy" from eleven analysts, with an average target price of $6.55 over the next year.
• The company's stock is currently trading at $4.53, down by 5.4%, with a 52-week low of $3.67 and a high of $8.94.
• GoodRx recently reported quarterly earnings of $0.09 EPS, exceeding expectations, and showed a revenue increase of 2.6% year-over-year, totaling $202.97 million.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eleven brokerages that are presently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $6.5455.

Several research firms have recently issued reports on GDRX. UBS Group cut their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. The Goldman Sachs Group cut their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Truist Financial cut their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, Wells Fargo & Company cut their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th.

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 4.17% of the company's stock.

Institutional Investors Weigh In On GoodRx

Several hedge funds have recently modified their holdings of GDRX. Geode Capital Management LLC increased its position in shares of GoodRx by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock valued at $4,986,000 after buying an additional 89,032 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in GoodRx during the 4th quarter worth $358,000. Barclays PLC lifted its holdings in shares of GoodRx by 18.4% in the fourth quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after buying an additional 25,815 shares during the period. Northern Trust Corp lifted its holdings in shares of GoodRx by 13.5% during the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after purchasing an additional 50,256 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in GoodRx during the fourth quarter valued at $314,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Price Performance

GDRX traded down $0.11 during trading hours on Monday, hitting $4.39. The company's stock had a trading volume of 1,336,869 shares, compared to its average volume of 1,061,916. The business's 50-day moving average price is $4.60 and its 200-day moving average price is $4.57. GoodRx has a 12 month low of $3.67 and a 12 month high of $8.94. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of 32.14, a P/E/G ratio of 2.00 and a beta of 1.24. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. The business had revenue of $202.97 million for the quarter, compared to analysts' expectations of $202.25 million. GoodRx had a net margin of 3.57% and a return on equity of 7.85%. The business's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.08 earnings per share. Sell-side analysts expect that GoodRx will post 0.13 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.